Menu

Blog

Archive for the ‘life extension’ category: Page 133

Apr 23, 2022

Morgan Levine is interviewed by Rhonda Patrick on Longevity. My picks on it

Posted by in categories: biotech/medical, chemistry, life extension

This is a 10-minute version with my picks on an hour-and-a-half interview on the longevity science made by Rhonda Patrick to Morgan Levine.

The link to the entire interview, which took place on April 12, 2022, is in the description of the video.

Continue reading “Morgan Levine is interviewed by Rhonda Patrick on Longevity. My picks on it” »

Apr 23, 2022

Sonia Arrison — Author, Analyst, Investor, Entrepreneur — Positively Impacting Human Longevity

Posted by in categories: biotech/medical, economics, life extension, singularity

Making positive impacts on human longevity — sonia arrison, author, analyst, investor, entrepreneur.


Sonia Arrison (https://soniaarrison.com/) is a best-selling author, analyst, entrepreneur, and investor.

Continue reading “Sonia Arrison — Author, Analyst, Investor, Entrepreneur — Positively Impacting Human Longevity” »

Apr 23, 2022

Future Of Aging & Cellular Reprogramming | Eleanor Sheekey Ep 4

Posted by in categories: biotech/medical, chemistry, life extension, media & arts

She gives a great analogy of slowing aging versus reversing aging, and I did not realize Yamanaka Factors were not so perfect in current use.


In this video Eleanor talks about the her view on Longevity Escape Velocity and reprogramming with Yamanaka factors and some of the issues around this technology.

Continue reading “Future Of Aging & Cellular Reprogramming | Eleanor Sheekey Ep 4” »

Apr 22, 2022

Different responses to DNA damage determine ageing differences between organs

Posted by in categories: biotech/medical, life extension

Organs age differently. To investigate the basis of organ-specific ageing we systematically compared at the tissue, stem cell and organoid level two organs representing ageing extremes, from accelera…

Apr 22, 2022

BioAge Announces First Cohort Dosed in Clinical Trial for Muscle Aging

Posted by in categories: biotech/medical, life extension

Trial will collect muscle aging biomarker data to inform Phase 2 trials and future development for muscle atrophy in hospitalised patients.

Apr 21, 2022

Artificial Heart Developer CARMAT Beats €40.5 Million Funding Goal

Posted by in categories: biotech/medical, finance, life extension

CARMAT, the developer of the world’s most advanced completely artificial heart has successfully raised €40.5 million in funding. The raise is set to finance the production of their Aeson artificial heart, which the company hopes will provide an alternative treatment option for people with heart failure – a condition affecting around 6.2 million adults in the US alone [1].

Longevity. Technology: Beating around 100,000 times per day, your heart works around the clock to keep your circulatory system ticking. The steady sound of your heartbeat is a comforting constant throughout your life. Forming the centre of the circulatory system, the heart continuously pumps blood around the body to deliver oxygen and nutrients to cells. Due to this constant work, our hearts can unfortunately wear out as we age, with cardiovascular diseases continuing to be the leading causes of death globally [2].

End-stage heart failure is a serious condition that occurs when the heart can no longer transport blood throughout the body effectively. It most often affects the left chamber of the heart, which pumps oxygen-rich blood around the body, leading to biventricular heart failure. Vital organs like the brain, liver and kidney fail to get enough oxygen and nutrients to function properly. With few treatment options, end-stage heart failure sometimes requires serious intervention like heart transplantation – considered the gold standard therapy. However, due to the global shortage in organ donors, this is not always possible and there is a gap for a therapeutic alternative that could have huge implications for longevity globally.

Apr 18, 2022

A Message from the SRF Board of Directors

Posted by in categories: biotech/medical, governance, life extension

The SENS Research Foundation Board of Directors has a singular focus – to help the Foundation develop, promote, and ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging. As the body responsible for ensuring the organization’s alignment with its mission, it is important our Board comprise leaders within the longevity field – visionaries dedicated to defeating the effects of aging permanently.

Many supporters have followed with interest our recent separation from our co-Founder Dr. Aubrey de Grey, and some have expressed concern regarding the possibility of our mission focus drifting off course. We remain firmly on-mission and continue to make real progress in our field, however, we acknowledge that we are the foundation we are today because of Dr. de Grey’s vision and leadership within the longevity movement. With this in mind, we have formally offered Dr. de Grey a Directorship within the Board of Directors.

His installment as a Director will be effective immediately upon the successful completion of the recommendations made by the accredited professional he has personally engaged, with a subsequent letter of recommendation to the Board of Directors supporting Dr. de Grey’s ability to fulfill the duties of Directorship. In this capacity, Dr. de Grey would lend his expertise to help steer the vision of the Foundation. Consistent with good governance and past practices, Dr. de Grey and the other members of the Board will approve the annual budget, review the annual audit, interview and hire executives, act as advocates for SRF, and largely ensure that the mission is being adhered to by the organization.

Apr 18, 2022

Dementia: Vitamin K may prevent cognitive decline

Posted by in categories: life extension, neuroscience

New research in rats suggests that vitamin K intake can improve cognitive abilities in the aging brain.

Apr 17, 2022

The Case against Death

Posted by in categories: education, life extension

By Ingemar Patrick Linden


A philosopher refutes our culturally embedded acceptance of death, arguing instead for the desirability of anti-aging science and radical life extension.

Ingemar Patrick Linden’s central claim is that death is evil. In this first comprehensive refutation of the most common arguments in favor of human mortality, he writes passionately in favor of antiaging science and radical life extension. We may be on the cusp of a new human condition where scientists seek to break through the arbitrarily set age limit of human existence to address aging as an illness that can be cured. The book, however, is not about the science and technology of life extension but whether we should want more life. For Linden, the answer is a loud and clear “yes.”

Continue reading “The Case against Death” »

Apr 17, 2022

AGE Products Impact Lifespan: Impact Of Hyperglycemia, Kidney Function, And The Microbiome

Posted by in categories: biotech/medical, life extension

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Papers referenced in the video:
Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan.
https://pubmed.ncbi.nlm.nih.gov/18599606/

Continue reading “AGE Products Impact Lifespan: Impact Of Hyperglycemia, Kidney Function, And The Microbiome” »